Herriot Tabuteau, Axsome CEO (Owen Hoffmann/Patrick McMullan via Getty Images)
Axsome's long delayed depression drug is back up for label discussions at the FDA, triggering a big spike in the share price
Axsome’s on-and-off quest to obtain an FDA approval for their depression drug AXS-05 is back on again.
After the markets closed on Monday, the biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.